Market Cap 1.77B
Revenue (ttm) 7.02M
Net Income (ttm) -157.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,248.72%
Debt to Equity Ratio 0.00
Volume 624,000
Avg Vol 1,253,874
Day's Range N/A - N/A
Shares Out 66.41M
Stochastic %K 29%
Beta 1.33
Analysts Strong Sell
Price Target $53.07

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 200 7500
Fax: 908 454 1911
Address:
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States
lucabrix
lucabrix Oct. 27 at 10:20 AM
$CLDX Novartis buys Avidity Bio for 12B$
0 · Reply
LeeEnnisEA
LeeEnnisEA Oct. 21 at 8:51 PM
$CLDX @Steve1545 i was wrong
1 · Reply
Quantumup
Quantumup Oct. 21 at 7:20 PM
Mizuho y'day🏁 $CLDX Outperform/$48 $NVS $REGN - $SNY JSPR $LLY TEVA ALLK Mizuho said: We are initiating coverage of Celldex Therapeutics with an Outperform rating and $48 PT as we see barzovolimab (anti-KIT mAb) as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. We believe barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit. With this, we performed probability modeling that we believe points to high probability of future statistical success in the ongoing Phase III trials for all-comers and the important subgroup of omalizumab-experienced patients, as well as clear opportunity to generate a best-in-indication efficacy profile. Altogether, we project $2.X.6B in risk-adjusted 2035 WW sales for barzolvolimab in chronic urticaria and expect positive Phase III data, as well as potential indication expansion to drive outperformance.
0 · Reply
lucabrix
lucabrix Oct. 21 at 3:39 PM
$CLDX Joseph Catanzaro from Mizuho set a target price of $48.0 on 10/21/2025 Etzer Darout from Barclays set a target price of $25.0 on 10/13/2025 (?????????) Edward Nash from Canaccord Genuity set a target price of $62.0 on 09/17/2025 David Lebowitz from Citigroup set a target price of $48.0 on 08/20/2025 Joseph Pantginis from HC Wainwright & Co. set a target price of $42.0 on 08/20/2025 Derek Archila from Wells Fargo set a target price of $38.0 on 08/20/2025 Trung Huynh from UBS set a target price of $38.0 on 05/09/2025
0 · Reply
Steve1545
Steve1545 Oct. 21 at 1:34 PM
$CLDX 52 week highs incoming
1 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:44 PM
Mizuho updates rating for Celldex Therapeutics ( $CLDX ) to Outperform, target set at 48.
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 20 at 1:26 PM
$IFRX Whats a Win? Current standard-of-care efficacy CSU, ~50-60% of patients respond partially to omalizumab (Xolair) $RHHBY but complete control is rare (<40%). Also why Roche often mentioned as a buyout. In HS, adalimumab $ABBV achieves HiSCR (primary endpoint) in ~50% at week 12, but placebo rates are ~25-30%, leaving high unmet need. Also why Abbie often mentioned as buyout candidate. In CSU, Historical Phase 2 benchmarks: Barzolvolimab $CLDX hit rapid UAS7 reductions in >50% with good tolerability; EVO756 showed 30% complete response at week 4. No yet approved. A "win" for $IFRX would mean clinically meaningful improvements over baseline, with rapid onset (e.g., by week 4) to highlight the oral, non-immunosuppressive profile. Even 25-35% responders with dose-dependent signals would signal upside, as it proves C5a inhibition works in antihistamine-refractory patients. **Differentiated MOA is significantly needed with no 1 drug doing the trick** Remember $MLTX ?
0 · Reply
lucabrix
lucabrix Oct. 15 at 7:26 PM
$CLDX Reply!
0 · Reply
Steve1545
Steve1545 Oct. 15 at 4:43 PM
0 · Reply
lucabrix
lucabrix Oct. 13 at 3:45 PM
$CLDX slow and strong uptrend
0 · Reply
Latest News on CLDX
Celldex Therapeutics: Rising High, With Room For Further Growth

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth


MoneyShow's Best Investment Ideas For 2024: Part 2

Jan 26, 2024, 5:30 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE


lucabrix
lucabrix Oct. 27 at 10:20 AM
$CLDX Novartis buys Avidity Bio for 12B$
0 · Reply
LeeEnnisEA
LeeEnnisEA Oct. 21 at 8:51 PM
$CLDX @Steve1545 i was wrong
1 · Reply
Quantumup
Quantumup Oct. 21 at 7:20 PM
Mizuho y'day🏁 $CLDX Outperform/$48 $NVS $REGN - $SNY JSPR $LLY TEVA ALLK Mizuho said: We are initiating coverage of Celldex Therapeutics with an Outperform rating and $48 PT as we see barzovolimab (anti-KIT mAb) as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. We believe barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit. With this, we performed probability modeling that we believe points to high probability of future statistical success in the ongoing Phase III trials for all-comers and the important subgroup of omalizumab-experienced patients, as well as clear opportunity to generate a best-in-indication efficacy profile. Altogether, we project $2.X.6B in risk-adjusted 2035 WW sales for barzolvolimab in chronic urticaria and expect positive Phase III data, as well as potential indication expansion to drive outperformance.
0 · Reply
lucabrix
lucabrix Oct. 21 at 3:39 PM
$CLDX Joseph Catanzaro from Mizuho set a target price of $48.0 on 10/21/2025 Etzer Darout from Barclays set a target price of $25.0 on 10/13/2025 (?????????) Edward Nash from Canaccord Genuity set a target price of $62.0 on 09/17/2025 David Lebowitz from Citigroup set a target price of $48.0 on 08/20/2025 Joseph Pantginis from HC Wainwright & Co. set a target price of $42.0 on 08/20/2025 Derek Archila from Wells Fargo set a target price of $38.0 on 08/20/2025 Trung Huynh from UBS set a target price of $38.0 on 05/09/2025
0 · Reply
Steve1545
Steve1545 Oct. 21 at 1:34 PM
$CLDX 52 week highs incoming
1 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:44 PM
Mizuho updates rating for Celldex Therapeutics ( $CLDX ) to Outperform, target set at 48.
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 20 at 1:26 PM
$IFRX Whats a Win? Current standard-of-care efficacy CSU, ~50-60% of patients respond partially to omalizumab (Xolair) $RHHBY but complete control is rare (<40%). Also why Roche often mentioned as a buyout. In HS, adalimumab $ABBV achieves HiSCR (primary endpoint) in ~50% at week 12, but placebo rates are ~25-30%, leaving high unmet need. Also why Abbie often mentioned as buyout candidate. In CSU, Historical Phase 2 benchmarks: Barzolvolimab $CLDX hit rapid UAS7 reductions in >50% with good tolerability; EVO756 showed 30% complete response at week 4. No yet approved. A "win" for $IFRX would mean clinically meaningful improvements over baseline, with rapid onset (e.g., by week 4) to highlight the oral, non-immunosuppressive profile. Even 25-35% responders with dose-dependent signals would signal upside, as it proves C5a inhibition works in antihistamine-refractory patients. **Differentiated MOA is significantly needed with no 1 drug doing the trick** Remember $MLTX ?
0 · Reply
lucabrix
lucabrix Oct. 15 at 7:26 PM
$CLDX Reply!
0 · Reply
Steve1545
Steve1545 Oct. 15 at 4:43 PM
0 · Reply
lucabrix
lucabrix Oct. 13 at 3:45 PM
$CLDX slow and strong uptrend
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 12:15 PM
Barclays has updated their rating for Celldex Therapeutics ( $CLDX ) to Underweight with a price target of 25.
0 · Reply
lucabrix
lucabrix Oct. 9 at 3:09 PM
$CLDX holding well despite the red day
0 · Reply
lucabrix
lucabrix Oct. 8 at 2:54 PM
$CLDX getting a bit of love!
0 · Reply
Steve1545
Steve1545 Oct. 8 at 2:53 PM
0 · Reply
lucabrix
lucabrix Oct. 3 at 2:54 PM
$CLDX XBI at 104, the big run has just started! Little bios are going to make me rich after long pains, and CLDX will follow
0 · Reply
Windee
Windee Oct. 3 at 12:43 PM
0 · Reply
Steve1545
Steve1545 Oct. 2 at 10:14 AM
1 · Reply
FactsPlease99
FactsPlease99 Sep. 30 at 8:17 PM
$CLDX knowing this guy is here is never good sign. Have never seen one stock go up when he is pumping it. ARWR is the one you should be buying but what would you know. ACInvestorBlog? LMFAO
0 · Reply
ArrcAngel
ArrcAngel Sep. 29 at 4:15 PM
$CLDX Ascending Triangle
0 · Reply
lucabrix
lucabrix Sep. 26 at 7:19 PM
$CLDX 27.70 UTL to crash
0 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 25 at 1:44 PM
$CLDX im buying this pullback.
0 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 25 at 1:41 PM
$CLDX im buying this pullback.
0 · Reply